News

According to the average brokerage recommendation (ABR), one should invest in Vertex (VRTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.

The fresh FDA approval allows the use of the cell therapy in patients as young as two years old with sickle cell disease (SCD) who have recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia (TDT).

VRTX gets FDA approval to expand Casgevy use in patients aged two and older with SCD or TDT, a first for genetic therapies in both inherited blood disorders.

Dyne pursues rare disease breakthroughs while Vertex leverages blockbuster profits for pipeline expansion, how do their risk profiles and financials compare?

Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers.

From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting financials and risk profiles.

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $491.34, denoting a +2.32% move from the preceding trading day.

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $475.12, indicating a +1.43% shift from the previous trading day.

The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.

If you are wondering whether Vertex Pharmaceuticals is priced fairly after its recent run, a good starting point is understanding what the current share price implies about future expectations. The stock last closed at US$466.79, with returns of 3.0% over the past week, 7.4% over the past month, 3.2% year to date, 3.7% over one year, 34.5% over three years and 137.2% over five years. This performance raises questions about how much of the story is already reflected in the price. Recent...

Vertex Pharmaceuticals recently reported Phase 3 data showing that its CRISPR-based therapy CASGEVY delivered strong clinical benefits and a consistent safety profile in children ages 5–11 with severe sickle cell disease and transfusion-dependent beta thalassemia, with all evaluable patients achieving the main trial goals. This pediatric dataset, presented at the European Hematology Association Congress and published in the New England Journal of Medicine, supports Vertex’s regulatory push...

Vertex Pharmaceuticals has been treading water for the past six months, recording a small loss of 1.6% while holding steady at $452.99. The stock also fell short of the S&P 500’s 9% gain during that period.

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

These companies don't typically compete directly with one another, but that might change soon.

VRTX is betting on kidney disease candidates like povetacicept and inaxaplin to drive long-term growth beyond its dominant cystic fibrosis franchise.

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $451.63, denoting a -1.6% move from the preceding trading day.

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.

The opportunity is enormous, but uncertainty remains.

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $458.99, denoting a +1.28% move from the preceding trading day.

They have at least one thing in common: An exciting pipeline.

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

After helping scale Vertex Pharmaceuticals from $3 billion to $13 billion in revenue, CFO and COO Charles Wagner says finance leaders must build organizations for opportunities that haven’t emerged yet.

The death crosses flashing on both Hershey (NYSE: HSY) and Vertex Pharmaceuticals (NASDAQ: VRTX) are a bearish technical signal that Wall Street is openly ignoring. Analyst consensus on both stocks is solidly bullish, with double-digit implied upside to consensus targets, and the institutional bid keeps appearing even as the 50-day moving averages drift below the ... The Death Cross Is Lying: Why Wall Street Is Still Loading Up on Hershey and Vertex

Vertex Pharmaceuticals reported pivotal pediatric data for CASGEVY for young children with severe sickle cell disease and beta thalassemia. The company released positive long term and very early age group results for cystic fibrosis therapies ALYFTREK and TRIKAFTA. Vertex initiated regulatory reviews to expand indications into younger populations across multiple regions. These updates come with Vertex Pharmaceuticals (NasdaqGS:VRTX) shares trading at $445.04 and a value score of 4,...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $444.41, denoting a +2% move from the preceding trading day.

Is VRTX a good stock to buy? We came across a bullish thesis on Vertex Pharmaceuticals Incorporated on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on VRTX. Vertex Pharmaceuticals Incorporated’s share was trading at $445.77 as of June 9th. VRTX’s trailing and forward P/E were 26.46 and 23.47 respectively according to Yahoo […]

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $435.76, signifying a -2.25% move from its prior day's close.